Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors

This study compares two approaches for treating a rare type of lung cancer called a pulmonary neuroendocrine tumor (carcinoid tumor): a targeted drug called surufatinib used alone, versus surufatinib combined with chemotherapy. **You may be eligible if...** - You are 18–75 years old - You have been diagnosed with a typical or atypical carcinoid tumor of the lung, confirmed by biopsy - Your cancer is measurable on scans - You have not previously received systemic (whole-body) treatment for this cancer, or you had early-stage treatment that ended at least 6 months before relapse - You are well enough to carry out daily activities (ECOG 0–1) **You may NOT be eligible if...** - You have previously received surufatinib or other anti-angiogenic (blood vessel-targeting) drugs - You have uncontrolled high blood pressure - You have had a heart attack, stroke, or significant heart failure in the past 6 months - You have active hepatitis B, hepatitis C, HIV, or cirrhosis - You have active brain metastases - You are pregnant or breastfeeding - You have had significant bleeding in the past 3 months Talk to your doctor to see if this trial is right for you.